Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioTools's quarterly accounts payable & accrued expense
increased
from Dec. 2025 ($16.10 Mil) to Mar. 2026 ($17.83 Mil) and
increased
from Mar. 2026 ($17.83 Mil) to Jun. 2026 ($31.42 Mil).
Standard BioTools's annual accounts payable & accrued expense
declined
from Dec. 2023 ($16.69 Mil) to Dec. 2024 ($14.50 Mil) but then
increased
from Dec. 2024 ($14.50 Mil) to Dec. 2025 ($16.10 Mil).
Standard BioTools Accounts Payable & Accrued Expense Historical Data
* Premium members only.
The historical data trend for Standard BioTools's Accounts Payable & Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools Accounts Payable & Accrued Expense Chart
Standard BioTools Accounts Payable & Accrued Expense Calculation
Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.
Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.
It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.
What does a Accounts Payable & Accrued Expense of $31.42 Mil mean?
Standard BioTools (LAB) has a Accounts Payable & Accrued Expense of $31.42 Mil as of Jun. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Standard BioTools and its competitors.
Is Standard BioTools' Accounts Payable & Accrued Expense too high?
Standard BioTools' current Accounts Payable & Accrued Expense is $31.42 Mil. Overall, Standard BioTools has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Accounts Payable & Accrued Expense compare to CV and ELMD?
Standard BioTools' Accounts Payable & Accrued Expense of $31.42 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Medical Devices & Instruments company?
A good Accounts Payable & Accrued Expense depends on the Medical Devices & Instruments industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Standard BioTools and its competitors. Standard BioTools's current Accounts Payable & Accrued Expense is $31.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (LAB) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.71, compared to a current price of $0.64 — trading 10.6% below its estimated fair value. The current Accounts Payable & Accrued Expense is $31.42 Mil. Standard BioTools' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Standard BioTools (LAB), the current Accounts Payable & Accrued Expense is $31.42 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be undervalued.
The current stock price of $0.64 is trading 10.6% below its estimated GF Value™ of $0.71.
GuruFocus considers Standard BioTools to be Modestly Undervalued.
Key valuation signals for LAB:
Accounts Payable & Accrued Expense: $31.42 Mil
GF Value™: $0.71 vs. price of $0.64 (10.6% below fair value)
No single metric tells the full story. See the LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
33GF Score
Get the complete analysis for LAB
Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LAB has been successfully added to your 
